NAV

2-Aminothiazoline

Identification

Generic Name
2-Aminothiazoline
DrugBank Accession Number
DB02335
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 102.158
Monoisotopic: 102.025168892
Chemical Formula
C3H6N2S
Synonyms
Not Available
External IDs
  • NSC-24626
  • NSC-3110
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UNitric oxide synthase, endothelialNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiazolines. These are heterocyclic compounds containing a five-member unsaturated aliphatic ring with one nitrogen atom, one sulfur atom, three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolines
Sub Class
Thiazolines
Direct Parent
Thiazolines
Alternative Parents
Isothioureas / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aliphatic heteromonocyclic compound / Azacycle / Carboximidamide / Hydrocarbon derivative / Isothiourea / Meta-thiazoline / Organic 1,3-dipolar compound / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
1,3-thiazole, primary amino compound (CHEBI:40889)
Affected organisms
Not Available

Chemical Identifiers

UNII
5JC2YZG56Q
CAS number
1779-81-3
InChI Key
REGFWZVTTFGQOJ-UHFFFAOYSA-N
InChI
InChI=1S/C3H6N2S/c4-3-5-1-2-6-3/h1-2H2,(H2,4,5)
IUPAC Name
4,5-dihydro-1,3-thiazol-2-amine
SMILES
NC1=NCCS1

References

Synthesis Reference

Jean-Christophe Carry, "2-aminothiazoline derivatives and process for preparing the same." U.S. Patent US20020198243, issued December 26, 2002.

US20020198243
General References
Not Available
PubChem Compound
15689
PubChem Substance
46506807
ChemSpider
14923
BindingDB
50150920
ChEBI
40889
ChEMBL
CHEMBL362148
ZINC
ZINC000018354955
PDBe Ligand
ATQ
PDB Entries
1d1w

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)85.3 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility12.2 mg/mLALOGPS
logP-0.24ALOGPS
logP0.21Chemaxon
logS-0.92ALOGPS
pKa (Strongest Basic)9.3Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area38.38 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity27.7 m3·mol-1Chemaxon
Polarizability10.08 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7301
Blood Brain Barrier+0.9797
Caco-2 permeable-0.5603
P-glycoprotein substrateNon-substrate0.657
P-glycoprotein inhibitor INon-inhibitor0.9767
P-glycoprotein inhibitor IINon-inhibitor0.9492
Renal organic cation transporterInhibitor0.5926
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.6778
CYP450 3A4 substrateNon-substrate0.7754
CYP450 1A2 substrateInhibitor0.8068
CYP450 2C9 inhibitorNon-inhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.6527
CYP450 2C19 inhibitorNon-inhibitor0.8693
CYP450 3A4 inhibitorNon-inhibitor0.9229
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8212
Ames testAMES toxic0.5685
CarcinogenicityNon-carcinogens0.9592
BiodegradationNot ready biodegradable0.69
Rat acute toxicity3.2495 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9506
hERG inhibition (predictor II)Non-inhibitor0.9535
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0zi0-9200000000-fe361661bba3bec58451
GC-MS Spectrum - EI-BGC-MSsplash10-0zfr-9600000000-5f7e0ed9711ed988a644
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-69c45ff343720ca5f9d0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-9700000000-dd39a8eed9c568afd465
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-0990341c1330518b4afc
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-9800000000-7392fcd34fa543ab83c8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9000000000-ee36075a76346866d445
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-ad12c97d73955f13dba2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-108.6216855
predicted
DarkChem Lite v0.1.0
[M-H]-124.62926
predicted
DeepCCS 1.0 (2019)
[M+H]+109.6370855
predicted
DarkChem Lite v0.1.0
[M+H]+126.62891
predicted
DeepCCS 1.0 (2019)
[M+Na]+109.1239855
predicted
DarkChem Lite v0.1.0
[M+Na]+134.54965
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Nitric oxide synthase, endothelial
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:15